GW Pharmaceuticals (NASDAQ:GWPH) – Analysts at Cantor Fitzgerald dropped their FY2018 EPS estimates for GW Pharmaceuticals in a report issued on Tuesday, May 22nd. Cantor Fitzgerald analyst E. Piros now forecasts that the biopharmaceutical company will post earnings per share of ($10.20) for the year, down from their prior estimate of ($9.58). Cantor Fitzgerald currently has a “Overweight” rating and a $205.00 target price on the stock.
GW Pharmaceuticals (NASDAQ:GWPH) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.22) by ($0.90). GW Pharmaceuticals had a negative net margin of 1,516.94% and a negative return on equity of 53.37%. The firm had revenue of $3.35 million for the quarter, compared to analyst estimates of $2.04 million. During the same period last year, the firm posted ($1.70) EPS. The business’s revenue was up 112.0% compared to the same quarter last year.
GWPH stock opened at $158.22 on Thursday. The stock has a market capitalization of $4.22 billion, a P/E ratio of -22.77 and a beta of 2.60. GW Pharmaceuticals has a fifty-two week low of $92.65 and a fifty-two week high of $160.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.32 and a quick ratio of 11.22.
Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC raised its position in GW Pharmaceuticals by 618.1% in the fourth quarter. Millennium Management LLC now owns 198,425 shares of the biopharmaceutical company’s stock worth $26,194,000 after acquiring an additional 170,792 shares in the last quarter. OppenheimerFunds Inc. raised its position in GW Pharmaceuticals by 78.4% in the fourth quarter. OppenheimerFunds Inc. now owns 178,430 shares of the biopharmaceutical company’s stock worth $23,555,000 after acquiring an additional 78,430 shares in the last quarter. Eqis Capital Management Inc. raised its position in GW Pharmaceuticals by 12.6% in the fourth quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 424 shares in the last quarter. Wells Fargo & Company MN raised its position in GW Pharmaceuticals by 23.2% in the fourth quarter. Wells Fargo & Company MN now owns 24,185 shares of the biopharmaceutical company’s stock worth $3,192,000 after acquiring an additional 4,549 shares in the last quarter. Finally, Prisma Capital Partners LP bought a new stake in GW Pharmaceuticals in the fourth quarter worth about $4,356,000. 71.69% of the stock is owned by institutional investors and hedge funds.
About GW Pharmaceuticals
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Receive News & Ratings for GW Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.